The development of mechanistically faithful models of congestive heart failure (CHF) biology is not readily feasible in cell culture or invertebrates as such systems fail to capture the complexity of multi- cellular or multi-organ processes. We have previously developed in vivo assays for complex multi- system phenotypes in the zebrafish, a screenable vertebrate, and exploited these in 'unbiased'screens for genetic and chemical modifiers. Adapting this integrated approach for CHF will allow us to identify the genes controlling CHF signaling hierarchies or small molecules that reverse CHF through novel mechanisms. These insights can be rapidly translated to other models for the dissection of CHF biology, and might also lead to novel diagnostic or therapeutic targets. We propose to develop a suite of core phenotypes and reporters for CHF in the zebrafish, and to combine these different elements in order to build a robust integrated in vivo assay for CHF in the following Specific Aims;
Aim 1. To develop a range of independent phenotypes and reporters for CHF in the larval zebrafish Using mechanistically faithful zebrafish models of human CHF, we will develop scalable phenotyping tools and in vivo reporters for multiple components of the syndrome, specifically;contractility, cardiac output, vasomotor tone, as well as natriuretic peptide, renin-angiotensin and other myocardial or systemic pathways implicated in CHF.
Aim 2. To define the optimal integrated zebrafish CHF assay for high-throughput screening We have recapitulated many human cardiovascular disease pathways in the larval zebrafish, at a stage when in vivo screening is feasible and high-resolution characterization of cardiac and vascular function is possible. We will validate multiple phenotypes and reporter lines in CHF models and test the feasibility of scaling to high-throughput while retaining specificity. We will adapt our optimized assays for automation in 96-well format, to generate an integrated assay with a robust z-factor for HTS.
Aim 3. To perform a pilot chemical screen for heart failure modifiers A pilot screen of 7,500 of structurally-diverse small molecules will be performed in a zebrafish model of CHF to validate the assay for large-scale screening. 'Hits'will be further evaluated in high-resolution secondary assays, as well as in existing zebrafish morphants or mutants that perturb myocardial heart failure pathways. This work will facilitate 'omic scale approaches to the genetics and epigenetics of CHF, and will generate an array of small molecules for manipulating CHF pathways. These genes or pathway probes can be rapidly translated into other experimental systems, and small molecule hits may represent potential drug leads for the antecedents of CHF. Importantly, this combination of screen-mode in vivo physiology with chemical biology or genetics is generalizable to many other biologic problems.

Public Health Relevance

The biology of heart failure is extremely complex and involves interactions between the heart and many other organs including kidney, skeletal muscle and brain, as well as the immune system. Since these features cannot all be recreated in cell culture, we are using the tiny transparent zebrafish to develop models for the entire heart failure condition. These models can then be screened directly to find genes or environmental factors that influence the development of heart failure, and to identify new drugs for this common disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL109264-02
Application #
8456074
Study Section
Instrumentation and Systems Development Study Section (ISD)
Program Officer
Adhikari, Bishow B
Project Start
2012-04-09
Project End
2015-02-28
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
2
Fiscal Year
2013
Total Cost
$407,956
Indirect Cost
$115,339
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
MacRae, Calum A (2015) A new phenotypic lexicon for accelerated translation: rise of the machines. Circulation 131:234-6
Cullere, Xavier; Plovie, Eva; Bennett, Paul M et al. (2015) The cerebral cavernous malformation proteins CCM2L and CCM2 prevent the activation of the MAP kinase MEKK3. Proc Natl Acad Sci U S A 112:14284-9
Guan, Jian; Mishra, Shikha; Qiu, Yiling et al. (2014) Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity. EMBO Mol Med 6:1493-507
Musso, Gabriel; Tasan, Murat; Mosimann, Christian et al. (2014) Novel cardiovascular gene functions revealed via systematic phenotype prediction in zebrafish. Development 141:224-35
Asimaki, Angeliki; Kapoor, Sudhir; Plovie, Eva et al. (2014) Identification of a new modulator of the intercalated disc in a zebrafish model of arrhythmogenic cardiomyopathy. Sci Transl Med 6:240ra74
Becker, Jason R; Chatterjee, Sneha; Robinson, Tamara Y et al. (2014) Differential activation of natriuretic peptide receptors modulates cardiomyocyte proliferation during development. Development 141:335-45
Guan, Jian; Mishra, Shikha; Shi, Jianru et al. (2013) Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. Basic Res Cardiol 108:378
Jay, Steven M; Murthy, Ashwin C; Hawkins, Jessica F et al. (2013) An engineered bivalent neuregulin protects against doxorubicin-induced cardiotoxicity with reduced proneoplastic potential. Circulation 128:152-61
Arndt, Anne-Karin; Schafer, Sebastian; Drenckhahn, Jorg-Detlef et al. (2013) Fine mapping of the 1p36 deletion syndrome identifies mutation of PRDM16 as a cause of cardiomyopathy. Am J Hum Genet 93:67-77
Huang, Chiu-Ju; Wilson, Val; Pennings, Sari et al. (2013) Sequential effects of spadetail, one-eyed pinhead and no tail on midline convergence of nephric primordia during zebrafish embryogenesis. Dev Biol 384:290-300

Showing the most recent 10 out of 24 publications